Stories about: ovarian cancer

One-two punch: Small peptides attack ovarian cancer cells and their environment

ovarian cancer psaptides
Serous ovarian carcinoma (Nephron via Wikimedia Commons)

Ovarian cancer is the fifth leading cause of cancer death among women. Tumors often remain silent until they have spread; as a result, many women go undiagnosed until the disease has already advanced. Ovarian cancer cells often develop resistance to chemotherapy with taxanes and platinum agents, leaving few therapeutic options for women with advanced disease.

Two small peptides could present a new approach to ovarian cancer and potentially other tumors. Derived from a naturally-occurring human protein, they forced tumors to shrink significantly in an animal model of metastatic ovarian cancer, report researchers from Boston Children’s Hospital’s Vascular Biology Program, the University of Bergen and Weill Cornell Medical College in Science Translational Medicine last week.

Read Full Story | Leave a Comment

Predicting cancer drug response: One or two genes don’t always tell the story

Measuring the total amount of DNA damage within a tumor’s cells could help doctors predict its vulnerability to drugs like cisplatin. (Haukeland universitetssjukehus/Flickr)

Drugs like cisplatin that break DNA are some of the strongest weapons we have against breast, ovarian and other cancers. The problem, common to every form of chemotherapy, is that cisplatin doesn’t work for everyone. Given the potential side effects that go along with the drug—including vomiting, hearing loss and muscle cramps, just to name a few—the decision to give it to a patient becomes something of a gamble: Does the benefit outweigh the risk?

There are tests that examine individual genes and which can give doctors a limited view as to which tumors might respond best to cisplatin. But a multicenter team co-led by Zoltan Szallasi, MD, of Boston Children’s Hospital’s Informatics Program (CHIP), thinks they may have a solution that looks beyond individual genes to see which tumors might succumb to cisplatin and other drugs like it.

Read Full Story | Leave a Comment